Monte Rosa Therapeutics, Inc. has entered into a Collaboration and License Agreement with F. Hoffmann-La Roche Ltd to develop molecular glue degraders against cancer or neurological disease targets, with Roche making upfront payments of $50 million and potential milestones exceeding $2 billion.